GlassScriptPhysician profile
Dawn M Barlow
NPI 1174644538
$4,463.69
in general payments reported to CMS, 2019-2025
39 companies · $668 in 2025
The $668 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $238 · 2021: $851 · 2022: $1,102 · 2023: $757 · 2024: $847 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,896.36 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $372.18 | 2023-2025 | Korlym |
| Lilly USA, LLC | $294.27 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $176.87 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $161.94 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $154.45 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $136.58 | 2021-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.18 | 2021-2024 | Ofev, Jardiance |
| Eisai INC. | $106.13 | 2020-2022 | |
| Amgen INC. | $79.09 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.70 | 2022-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.64 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $63.05 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $61.57 | 2022-2023 | Rexulti |
| Pfizer INC. | $58.43 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.